You are here

ELDEC PHARMACEUTICALS INC.

Company Information
Address
510 MEADOWMONT VILLAGE CIR STE 364
CHAPEL HILL, NC 27517-7584
United States



Information

UEI: LJBWLKDBEM17

# of Employees: 3


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Novel Peptide Immunomodulators for Treating Sepsis

    Amount: $259,121.00

    Novel Peptide Immunomodulators for Treating Sepsis Sepsis is a life-threatening clinical condition which results from a dysregulation of host immune responses to infection, which leads to multi-organ ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Novel Peptide Fusion Inhibitors for the Treatment of COVID-19

    Amount: $300,000.00

    PROJECT SUMMARYCOVID-19 is caused by inhalation of the latest coronavirus (CoV) SARS-CoV-2 into the lungs, and airway epithelia are particularly susceptible to uptake this virus. Extensive evidence in ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  3. Novel Strategies to Clear Bacteria from the CF Lung

    Amount: $2,072,426.00

    Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene. CF airways are immunocompromised and become colonized with bacteria soon after ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  4. ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung

    Amount: $1,988,078.00

    Abstract Hospital acquired pneumonia (HAP) is most common cause of mortality in intensive care units and the 2nd most common nosocomial infection in the US. P. aeruginosa, S. aureus (including MRSA) a ...

    STTRPhase II2021Department of Health and Human Services National Institutes of Health
  5. ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung

    Amount: $300,000.00

    Hospital acquired pneumonia (HAP) is most common cause of mortality in intensive care units and the 2nd most common nosocomial infection in the US. P. aeruginosa, S. aureus (including MRSA) and other ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  6. Peptide therapies for treating CF lung inflammation

    Amount: $224,865.00

    Abstract Lung disease is the major cause of morbidity and mortality in cystic fibrosisCFpatientsHerea viscous cycle of infection and inflammation lead to persistent neutrophilia and bronchiectasis tha ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government